IPA Says Indian Pharmaceutical Industry Going to Have Marketing Code
According to Indian Pharmaceutical Alliance (IPA) the pharmaceutical industry has agreed in principle to enforce a code that will restrict […]
Say something
According to Indian Pharmaceutical Alliance (IPA) the pharmaceutical industry has agreed in principle to enforce a code that will restrict […]
Indian drug firm Strides Arcolab has received USFDA approval for the generic Fluorouracil Injection which will be used to treat […]
The RxNorm clinical drugs standard has been enhanced.
At a time when global multinational drug makers are slashing their workforces to reduce costs, their Indian counterparts are on a hiring spree.
[This article was published in the August 2008 issue of the eHEALTH Magazine (https://www.ehealthonline.org)]
The demand for a medicinal product brings with it the issues of Safety and Efficacy. Regulators can play a pivotal role in monitoring the medicinal
New guidelines, issued by the Department of Health, call for more partnerships between the NHS and drug companies, stressing they should be “of mutual benefit with the principal beneficiary being the patient”.
Pharmaceutical firm Merck Ltd announced recently that it has partnered with software firm Cirrius Wireless Technologies for providing mobile-based solution, marketing network and activation system (MANAS) to its sales representatives across the country.
India and other developing countries are set to lobby hard for funding mechanisms to develop medicines,
mostly aimed at neglected diseases such as tuberculosis and malaria, at a forum set up by the World Health Organization or WHO. Developed countries have long maintained that patents are sufficient incentive for innovation.
Cellworks Research India, the Bangalore-based research and development (R&D) wing of Cellworks Group Inc (California-headquartered company), has assisted Chennai-based Orchid Chemicals and Pharmaceuticals by providing system biology technology in carrying out ongoing New Chemical Entity (NCE) research programme.
IBM is targeting multi-billion dollar health business opportunities in India. The company has plans to tap opportunities worth $1 billion each in the Indian pharmaceuticals and health service segments over the next 3-4 years.
IBM is targeting multi-billion dollar health business opportunities in India. The company has plans to tap opportunities worth $1 billion each in the Indian pharmaceuticals and health service segments over the next 3-4 years.
The pharma sector may have underperformed in the Sensex , but companies providing contract research and manufacturing services (CRAMS) to global pharma companies have given good returns.
IBM is targeting multi-billion dollar health business opportunities in India. The company has plans to tap opportunities worth $1 billion each in the Indian pharmaceuticals and health service segments over the next 3-4 years.